trending Market Intelligence /marketintelligence/en/news-insights/trending/mteipxutgulrukx8obg9zw2 content esgSubNav
In This List

Titan Pharmaceuticals falls out of compliance with Nasdaq listing rule

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Titan Pharmaceuticals falls out of compliance with Nasdaq listing rule

South San Francisco, Calif.-based healthcare company Titan Pharmaceuticals Inc. said it was no longer in compliance with one of Nasdaq's listing requirements.

Specifically, the company has been unable to maintain a minimum bid price of $1 per share for continued listing on the stock exchange.

The company has until Nov. 26 to regain compliance, and the development has no immediate effect on the company's listing on the Nasdaq capital market.